HedgePath Pharmaceuticals Inc. has changed its name to Inhibitor Therapeutics Inc. The company is narrowing its focus on commercializing therapeutics that inhibit the progression of cancerous and noncancerous proliferation disorders.
The Tampa, Fla.-based biopharmaceutical company will change its ticker symbol to INTI from HPPI to reflect the rebranding. It will also unveil a new website focusing on its development of a U.S. Food and Drug Administration-approved formulation called Suba-Itraconazole for treating systematic fungal infections.
The company plans to hold discussions in 2020 with the FDA to advance its phase 2b clinical program to study Suba-Itraconazole in patients with late-stage lung cancer, it said in a press release.
